Whitehawk Therapeutics (WHWK) Equity Average (2018 - 2025)
Historic Equity Average for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to $164.6 million.
- Whitehawk Therapeutics' Equity Average rose 12296.91% to $164.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $164.6 million, marking a year-over-year increase of 12296.91%. This contributed to the annual value of $78.8 million for FY2024, which is 4017.86% down from last year.
- According to the latest figures from Q3 2025, Whitehawk Therapeutics' Equity Average is $164.6 million, which was up 12296.91% from $196.9 million recorded in Q2 2025.
- In the past 5 years, Whitehawk Therapeutics' Equity Average registered a high of $196.9 million during Q2 2025, and its lowest value of $37.1 million during Q2 2021.
- Its 5-year average for Equity Average is $116.3 million, with a median of $124.8 million in 2023.
- As far as peak fluctuations go, Whitehawk Therapeutics' Equity Average surged by 21429.49% in 2022, and later crashed by 4568.0% in 2024.
- Whitehawk Therapeutics' Equity Average (Quarter) stood at $143.7 million in 2021, then increased by 13.98% to $163.7 million in 2022, then tumbled by 31.79% to $111.7 million in 2023, then crashed by 45.68% to $60.7 million in 2024, then skyrocketed by 171.32% to $164.6 million in 2025.
- Its last three reported values are $164.6 million in Q3 2025, $196.9 million for Q2 2025, and $137.1 million during Q1 2025.